Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
EditorialEditorial

Six-Minute Walk Test in Scleroderma-Associated Pulmonary Arterial Hypertension: Are We Counting What Counts?

SUSHMITA PAMIDI and SANJAY MEHTA
The Journal of Rheumatology February 2009, 36 (2) 216-218; DOI: https://doi.org/10.3899/jrheum.081243
SUSHMITA PAMIDI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SANJAY MEHTA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sanjay.mehta@lhsc.on.ca
  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Everything that can be counted does not necessarily count;

Everything that counts cannot necessarily be counted

—Albert Einstein

Scleroderma-associated Pulmonary Arterial Hypertension

Systemic scleroderma (SSc) is a multisystem disease with protean manifestations, but pulmonary involvement is the leading cause of mortality. Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are 2 serious pulmonary complications of SSc that commonly cause clinical symptoms of dyspnea and exercise intolerance, can be associated with severe functional limitation, and often have a poor prognosis for longterm survival.

SSc-associated PAH (SSc-PAH) is a serious disease of progressive pulmonary vascular obliteration characterized by persistent elevation of pulmonary artery pressure (PAP) and pulmonary vascular resistance (PVR). Untreated SSc-PAH usually results in right-sided heart failure and high risk of death. The average survival in SSc patients diagnosed with PAH is 1–2 years1–3. Patients with SSc-PAH have a worse prognosis than most other PAH patients, including primary or idiopathic PAH (IPAH)4,5.

Many new PAH-specific therapies have been studied and are available for the treatment of patients with SSc-PAH. These include prostacyclin derivatives (intravenous epoprostenol, subcutaneous or intravenous treprostinil), a novel family of oral endothelin receptor antagonists (bosentan, sitaxsentan, and ambrisentan), as well as an oral phosphodiesterase type 5 inhibitor (sildenafil)6.

Treatment of PAH patients, including SSc-PAH, with these PAH-specific medications is associated with subjective and objective clinical benefit. Given that PAH is a disease of disturbed pulmonary hemodynamics, reductions in mean PAP and PVR, as well as improved right ventricular (RV) function, as evidenced by increased cardiac output, have been expectations of PAH therapy. However, repeated assessment of pulmonary hemodynamics by invasive rightheart catheterization is not feasible, and not necessarily indicated. Doppler echocardiographic assessment of RV systolic pressure (RVSP) is commonly used as a surrogate for systolic PAP. Moreover, other echo parameters, such as presence of pericardial effusion and degree of tricuspid annular displacement, are markers of PAH prognosis7,8. However, echo may not be a reliable measure of PAH severity because of lack of consensus on grading severity of these parameters, inconsistent technical rigor and expertise among echo technicians and physicians, and patient factors such as body habitus. Several studies have compared echoestimated RVSP with systolic PAP determined by rightheart catheterization, reporting good echo specificity (85%–96%), but generally poor sensitivity (58%–80%) for the detection of elevated PAP3,9

Clinical parameters are commonly used in the monitoring of PAH patients over time, including symptoms and physical examination evidence of right-sided heart failure. The World Health Organization (WHO) modification of the New York Heart Association (NYHA) functional class scoring system (class I to IV) correlates with PAH survival10, and can be used to assess stability versus decline in an individual patient. However, it remains unclear and controversial as to how to best assess the severity of PAH in an individual patient, and how to define or measure a clinical benefit of PAH treatment.

See Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma, page 330

Exercise Capacity in Scleroderma-associated PAH

The most common clinical features of PAH are dyspnea and exercise intolerance. As such, the objective measurement of exercise capacity has long been considered useful and relevant in the assessment of the severity of PAH, as well as the routine monitoring of PAH patients over time. Exercise requires a global and integrated response of many systems, including cardiac (increased cardiac output), peripheral vascular (increased muscle blood flow), respiratory (increased ventilation for O2 uptake and CO2 clearance), hematologic (blood carries and delivers O2), and musculoskeletal and metabolic systems (aerobic and anaerobic generation of ATP or energy).

The gold standard for evaluation of exercise capacity is the incremental, maximal, symptom-limited, treadmill, or cycle cardiopulmonary exercise test (CPET). CPET is a robust technique for assessment of the function of several major systems involved in exercise, including cardiovascular, respiratory, and metabolic. As such, CPET quantifies overall exercise capacity, and can identify the specific physiologic limitation to exercise, including unfitness, obesity, hypoxemia, and cardiovascular or respiratory disease. However, in order to obtain the most useful diagnostic information on physiologic limitations to exercise, CPET also requires a maximal effort by the patient, and this can be difficult and risky for some severely ill patients with PAH. Moreover, CPET requires specific exercise equipment and measurement systems, staff technical expertise, and significant medical/scientific physiologic expertise and experience with exercise testing. All these aspects are essential to obtain valid, reliable CPET data and an accurate interpretation.

Because of these concerns, the routine clinical use of CPET to assess exercise capacity in PAH patients may not be feasible or appropriate. Indeed, among the randomized clinical trials (RCT) of PAH therapies, maximal exercise capacity by CPET was selected as the primary outcome measure in only a single study of the endothelin receptor antagonist sitaxsentan. The lack of experience of many centers with CPET contributed to a negative outcome, as there was no significant difference between sitaxsentan and placebo-treated subjects in CPET maximal exercise capacity, despite significant improvements in several other parameters of PAH11.

A practical and simple alternative to CPET to determine exercise capacity is the 6-minute walk test (6MWT). The 6MWT is a simple, safe, noninvasive, reproducible test of exercise capacity12,13. In contrast to CPET, the 6MWT reflects a submaximal level of exertion that is more consistent with the effort required for daily physical activities. It is noteworthy that unlike CPET, the 6MWT does not provide information on the physiologic mechanism of exercise limitation13.

The 6MWT does not require any special exercise equipment or advanced training for staff, and thus is a practical method to repeatedly assess exercise capacity over time. Parameters that should be recorded include the distance covered during the 6MWT (6MWD), the level of patient respiratory effort, as reflected by the Borg dyspnea index, and arterial oxygen saturation by pulse oximetry.

6MWD has been found to correlate with WHO/NYHA functional class in patients with IPAH10,14 and specifically in SSc-PAH patients10. Moreover, 6MWD strongly and independently predicts prognosis for survival in IPAH14,15. For example, survival was significantly worse in WHO/NYHA class III and IV IPAH patients who walked ≤ 250 m at baseline prior to therapy, or < 380 m after 3 months of intravenous epoprostenol15.

6MWT has also become the most popular primary endpoint in RCT of medical therapies for PAH. For example, in the first RCT of a PAH-specific therapy in patients with SSc-PAH, median 6MWD improved 108 m in 56 patients with SSc-PAH treated with intravenous epoprostenol versus placebo16. Placebo-controlled RCT of all other available PAH therapies have also reported significant improvements in mean 6MWD. Importantly, the benefit in exercise capacity with PAH therapy may not be similar in SSc-PAH and IPAH patients. For example, bosentan increased 6MWD in IPAH patients, but prevented 6MWD deterioration in SSc-PAH patients17. Finally, all recent RCT of PAH therapies have included more patients with milder disease, specifically WHO/NYHA functional class II. In such PAH patients with better baseline exercise capacity, as reflected by higher 6MWD, the 6MWT may be limited by a “ceiling effect,” and may not be as robust in demonstrating an improvement in response to PAH-specific medical therapy.

In addition to the actual 6MWD, the degree of oxygen desaturation has been found to correlate with prognosis in IPAH patients18. Similarly, oxygen desaturation ≥ 4% during 6MWT in SSc patients correlated with echo-measured pulmonary artery systolic pressure ≥ 30 mm Hg, as well as advanced age, higher dyspnea index, and radiographic fibrosis19.

Because of its simplicity, reproducibility, and validity in reflecting PAH severity, 6MWT has been widely accepted, and is now recommended and routinely used in the assessment of PAH patients, prognostication, and for monitoring response to therapy. However, the 6MWT has never been specifically validated as a measure of cardiopulmonary exercise capacity in patients with SSc-PAH. Although 6MWD is clearly sensitive to the presence of cardiovascular and pulmonary complications of SSc, such as PAH, SSc patients are also limited by musculoskeletal dysfunction and pain as shown by Garin and colleagues in this issue of The Journal20.

Demographic and anthropometric variables such as age, height, and weight may have major effects on 6MWT. As such, the simple use of absolute 6MWD to assess an individual’s exercise capacity may not be as valid as adjusting 6MWD for the above factors, or expressing 6MWD as a percentage of a predicted value21.

The above limitations need to be resolved through further study before the routine use of 6MWT can be recommended for the management of SSc-PAH. It is also clear that new measures of PAH clinical disease severity, especially RV function, need to be developed, studied, and validated. Such outcome measures will be important in future RCT of new PAH therapies, as well as useful assessment tools for clinicians to better monitor individual PAH patients and assess the effectiveness of PAH therapy.

Footnotes

  • Dr. Mehta has received consulting and speaking fees (Actelion, GSK, Pfizer, United Therapeutics), and clinical investigator fees (Actelion, GSK, Lilly, Pfizer, United Therapeutics).

REFERENCES

  1. 1.↵
    1. Lee P,
    2. Langevitz P,
    3. Alderdice CA,
    4. et al
    . Mortality in systemic sclerosis (scleroderma). Q J Med 1992;82:139–48.
    OpenUrlAbstract/FREE Full Text
  2. 2.
    1. Kawut SM,
    2. Taichman DB,
    3. Archer-Chicko CL,
    4. Palevsky HI,
    5. Kimmel SE
    . Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003;123:344–50.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Mukerjee D,
    2. St. George D,
    3. Coleiro B,
    4. et al
    . Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088–93.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Girgis RE,
    2. Mathai SC,
    3. Krishnan JA,
    4. Wigley FM,
    5. Hassoun PM
    . Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant 2005;24:1626–31.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Fisher MR,
    2. Mathai SC,
    3. Champion HC,
    4. et al
    . Clinical differences between idiopathic and sclerodermarelated pulmonary hypertension. Arthritis Rheum 2006;54:3043–50.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Badesch DB,
    2. Abman SH,
    3. Simonneau G,
    4. Rubin LJ,
    5. McLaughlin VV
    . Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917–28.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Raymond RJ,
    2. Hinderliter AL,
    3. Willis PW,
    4. et al
    . Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002;39:1214–9.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Forfia PR,
    2. Fisher MR,
    3. Mathai SC,
    4. et al
    . Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006;174:1034–41.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Hsu VM,
    2. Moreyra AE,
    3. Wilson AC,
    4. et al
    . Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 2008;35:458–65.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Humbert M,
    2. Sitbon O,
    3. Chaouat A,
    4. et al
    . Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023–30.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Barst RJ,
    2. Langleben D,
    3. Frost A,
    4. et al
    . Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441–7.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Guyatt GH,
    2. Sullivan MJ,
    3. Thompson PJ,
    4. et al
    . The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. CMAJ 1985;132:919–23.
    OpenUrlAbstract
  13. 13.↵
    1. American Thoracic Society
    . ATS Statement: guidelines for the sixminute walk test. Am J Respir Crit Care Med 2002;166:111–7.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Miyamoto S,
    2. Nagaya N,
    3. Satoh T,
    4. et al
    . Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487–92.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Sitbon O,
    2. Humbert M,
    3. Nunes H,
    4. et al
    . Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780–8.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Badesch DB,
    2. Tapson VF,
    3. McGoon MD,
    4. et al
    . Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425–34.
    OpenUrlPubMed
  17. 17.↵
    1. Rubin LJ,
    2. Badesch DB,
    3. Barst RJ,
    4. et al
    . Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896–903.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Paciocco G,
    2. Martinez FJ,
    3. Bossone E,
    4. et al
    . Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J 2001;17:647–52.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Villalba WO,
    2. Sampaio-Barros PD,
    3. Pereira MC,
    4. et al
    . Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. Chest 2007;131:217–22.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Garin MC,
    2. Highland KB,
    3. Silver RM,
    4. Strange C
    . Limitations to the six-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol 2009;36:330–6.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Enright PL,
    2. Sherrill DL
    . Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 1999;158:1394–7.
    OpenUrl
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 36, Issue 2
1 Feb 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Six-Minute Walk Test in Scleroderma-Associated Pulmonary Arterial Hypertension: Are We Counting What Counts?
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Six-Minute Walk Test in Scleroderma-Associated Pulmonary Arterial Hypertension: Are We Counting What Counts?
SUSHMITA PAMIDI, SANJAY MEHTA
The Journal of Rheumatology Feb 2009, 36 (2) 216-218; DOI: 10.3899/jrheum.081243

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Six-Minute Walk Test in Scleroderma-Associated Pulmonary Arterial Hypertension: Are We Counting What Counts?
SUSHMITA PAMIDI, SANJAY MEHTA
The Journal of Rheumatology Feb 2009, 36 (2) 216-218; DOI: 10.3899/jrheum.081243
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Scleroderma-associated Pulmonary Arterial Hypertension
    • Exercise Capacity in Scleroderma-associated PAH
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Microdissecting Epigenetic Pathways in Oligoarticular Juvenile Idiopathic Arthritis: A New Avenue in Transforming Growth Factor β?
  • Ro52, Myositis, and Interstitial Lung Disease
  • Sex Effect in Psoriatic Arthritis
Show more Editorial

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire